-
1.发明授权
-
公开(公告)号：EP3129909B1
公开(公告)日：2020-09-16
申请号：EP15721065.9
申请日：2015-04-08
申请人： Metabolon, Inc.
发明人： MILBURN, Michael V. , RYALS, John A. , GUO, Lining , ECKHART, Andrea , WULFF, Jacob , KENNEDY, Adam D. , JÖNSSON, Thomas J. , MICHALEK, Ryan Douglas , WITTMANN, Bryan , MITCHELL, Matthew
IPC分类号： G01N33/50
-
3.发明授权
公开(公告)号：EP2486504B1
公开(公告)日：2020-05-13
申请号：EP10774032.6
申请日：2010-10-01
申请人： Metabolon Inc.
IPC分类号： G16B40/10
-
公开(公告)号：EP3491004A1
公开(公告)日：2019-06-05
申请号：EP17751177.1
申请日：2017-07-27
申请人： Metabolon, Inc.
发明人： ZHANG, Qibo , EVANS, Anne, M.
IPC分类号： C07K5/062 , A61K38/05 , C07D207/16
-
公开(公告)号：EP3410115A1
公开(公告)日：2018-12-05
申请号：EP18183240.3
申请日：2014-05-13
申请人： Metabolon, Inc.
IPC分类号： G01N33/493
CPC分类号： G01N33/6893 , G01N33/5308 , G01N33/64 , G01N33/6848 , G01N33/70 , G01N2570/00 , G01N2800/347 , G01N2800/50 , G01N2800/52 , G01N2800/56
摘要： Biomarkers of kidney function and methods for using said biomarkers for assessing kidney function, monitoring kidney function, diagnosing acute kidney injury, and diagnosing chronic kidney disease are provided. Also provided are suites of small molecule entities as biomarkers for chronic kidney disease.
-
公开(公告)号：EP3221463A4
公开(公告)日：2018-07-25
申请号：EP15860608
申请日：2015-11-18
申请人： METABOLON INC
CPC分类号： G01N33/92 , G01N33/50 , G01N33/5023 , G01N33/6806 , G01N33/82 , G01N2560/00 , G01N2570/00 , G01N2800/085 , G01N2800/56 , G01N2800/7052
摘要： Biomarkers of NASH, NAFLD, and fibrosis and methods for diagnosis (or aiding in the diagnosis) of NAFLD, NASH and/or fibrosis are described herein. Additionally, methods of distinguishing between NAFLD and NASH, methods of classifying the stage of fibrosis, methods of determining the severity of liver disease, methods of determining the severity of liver disease or fibrosis, and methods of monitoring progression/regression of NASH, NAFLD, and/or fibrosis are described herein.
-
公开(公告)号：EP3254105A1
公开(公告)日：2017-12-13
申请号：EP16715645.4
申请日：2016-02-04
申请人： Metabolon, Inc.
发明人： MILLER, Luke , ADAM, Klaus, Peter , MILBURN, Michael, V. , COBB, Jeffery, E. , EVANS, Anne, M. , ZHANG, Qibo
IPC分类号： G01N33/50 , A61K31/685 , G01N33/68
CPC分类号： G01N33/50 , A61K31/137 , A61K31/155 , A61K31/341 , A61K31/4439 , A61K31/485 , A61K31/7048 , C07D307/33 , C07K16/44 , C07K2317/56 , C07K2319/00 , G01N33/5008 , G01N33/507 , G01N33/6893 , G01N2800/042 , G01N2800/52
摘要： The present invention provides a method for diagnosing a disease or disorder selected from the group consisting of insulin resistance, a metabolic disorder, diabetes and pre-diabetes in a subject. The method comprises the step of determining the level of a compound represented by structural formula (VI): or a salt thereof. Compositions and method of making thereof are also described.
-
公开(公告)号：EP3221463A1
公开(公告)日：2017-09-27
申请号：EP15860608.7
申请日：2015-11-18
申请人： Metabolon, Inc.
CPC分类号： G01N33/92 , G01N33/50 , G01N33/5023 , G01N33/6806 , G01N33/82 , G01N2560/00 , G01N2570/00 , G01N2800/085 , G01N2800/56 , G01N2800/7052
摘要： Biomarkers of NASH, NAFLD, and fibrosis and methods for diagnosis (or aiding in the diagnosis) of NAFLD, NASH and/or fibrosis are described herein. Additionally, methods of distinguishing between NAFLD and NASH, methods of classifying the stage of fibrosis, methods of determining the severity of liver disease, methods of determining the severity of liver disease or fibrosis, and methods of monitoring progression/regression of NASH, NAFLD, and/or fibrosis are described herein.
摘要翻译： 本文描述了NASH，NAFLD和纤维化的生物标志物和用于诊断（或帮助诊断）NAFLD，NASH和/或纤维化的方法。 此外，还可区分NAFLD和NASH的方法，纤维化分期方法，确定肝脏疾病严重程度的方法，确定肝脏疾病或纤维化严重程度的方法以及监测NASH，NAFLD进展/退化的方法， 和/或纤维化在本文中描述。
-
9.发明公开
公开(公告)号：EP3215633A1
公开(公告)日：2017-09-13
申请号：EP15856657.0
申请日：2015-11-04
申请人： Metabolon, Inc.
发明人： LONERGAN, Shaun , RYALS, John, A. , MILBURN, Michael, V. , KENNEDY, Adam , GUO, Lining , LAWTON, Kay, A.
CPC分类号： G01N33/50 , G01N2570/00 , G06F19/18
摘要： Methods using a combination of metabolomics and computer technology to determine sequence variants with potential negative or detrimental effects and enable the classification of a variant with an unknown or uncertain clinical significance from VUS status to benign, pathogenic or advantageous are described. For example, methods of using metabolomics to expedite personalized medicine based on genomic sequence analysis are described. Using metabolic profiles to determine (or aid in determining) the significance of genetic variants and enable the identification of diagnostic variants (those variants having a detrimental health affect) for use in personalized medicine is described. Further, using metabolic profiles to determine the presence of advantageous variants that may have a positive effect on patient health is also described.
摘要翻译： 描述了使用代谢组学和计算机技术的组合来确定具有潜在负面或有害作用的序列变体，并且能够将具有未知或不确定临床显着性的变体从VUS状态分类为良性，致病性或有利的方法。 例如，描述了使用代谢组学来加速基于基因组序列分析的个性化药物的方法。 描述了使用代谢谱来确定（或帮助确定）遗传变异体的重要性并且能够鉴定用于个性化医学的诊断变体（那些具有有害健康影响的变体）。 此外，还描述了使用代谢谱来确定可能对患者健康有积极影响的有利变体的存在。
-
10.发明公开BIOMARKERS RELATED TO INSULIN RESISTANCE PROGRESSION AND METHODS USING THE SAME 有权生物标记与胰岛素抗性发展及其方法使用连接
公开(公告)号：EP2951313A1
公开(公告)日：2015-12-09
申请号：EP14746017.4
申请日：2014-01-16
申请人： Metabolon, Inc.
IPC分类号： C12Q1/54
CPC分类号： G01N33/6893 , G01N33/5308 , G01N2333/46 , G01N2800/042 , G01N2800/32 , G01N2800/324 , G01N2800/50 , G01N2800/52 , G01N2800/60 , G06F19/00 , G16H50/30
摘要： Biomarkers relating to insulin resistance and insulin resistance-related disorders are provided, as well as methods for using such biomarkers as biomarkers for insulin resistance, dysglycemia, type-2 diabetes, and cardiovascular disease. In addition, methods for monitoring the respective disorders or conditions of a subject are also provided. Also provided are suites of small molecule entities as biomarkers for insulin resistance, dysglycemia, type-2 diabetes, and cardiovascular disease.
-
-
-
-
-
-
-
-
-
搜索结果
107 条记录 (耗时 0.022 秒)
